Efficacy evaluation of imatinib treatment in patients with gastrointestinal stromal tumors: A meta-analysis

Table 1 Main characteristics of all studies included in the meta-analysis

Author	Dose distribution	Cumulative response (%)	Genotype	n
				KIT	Exon 11	Exon 9	WT
Debiec-Rychter et al[14], 2006	400 mg/800 mg	56	Exon 11, 9, 13, 17	315	248	58	52
			WT
Wardelmann et al[15], 2006	NA	50	Exon 11, 9	29	22	7	3
			WT
Yeh et al[16], 2007	400 mg	52	Exon 11, 9	49	40	9	5
			WT
Rutkowski et al[17], 2007	400 mg/800 mg	63	Exon 11, 9, 13, 17	63	52	9	19
			WT
Heinrich et al[18], 2008	400 mg/800 mg	56	Exon 11, 9, 8, 13, 17	325	283	32	67
			WT

WT: Wide type; NA: Not available.